For those unfamiliar with science journalese, this study compares prednisolone AND azathiprine to those treated with prednisolone only. Both are commonly used to treat IMHA. This study found no difference. The full paper is free at the link below.
http://www.biomedcentral.com/1746-6148/7/15
Lack of evidence of a beneficial effect of
azathioprine in dogs treated with prednisolone for idiopathic
immune-mediated hemolytic anemia: a retrospective cohort study
Christine J Piek1 , Willem Evert van Spil1 , Greet Junius2 and Aldo Dekker3
1
Department of Clinical Sciences of Companion Animals, Utrecht,
Utrecht University, PO Box 80154, 3508 TD Utrecht, The Netherlands
2
Dierenkliniek Randstad, Frans Beirenslaan 155, 2150 Borsbeek, Belgium
3
Central Institute for Animal Disease Control, P.O. Box 2004, 8203 AA Lelystad, The Netherlands
author email corresponding author email
BMC Veterinary Research 2011,
7:15doi:10.1186/1746-6148-7-15
The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1746-6148/7/15
Received: |
7 October 2010 |
Accepted: |
13 April 2011 |
Published: |
13 April 2011 |
©
2011 Piek et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background
Azathioprine is used as an immunosuppressant in canine
immune-mediated hemolytic anemia (IMHA), but this potentially toxic and
carcinogenic drug has not been proven to be beneficial. The aim of this
study was to determine the difference in outcome and survival of dogs
with idiopathic IMHA treated with a protocol that included azathioprine
and prednisolone versus a protocol that included prednisolone alone.
Results
The study included 222 dogs with a hematocrit lower than 0.30 L/L and
either a positive Coombs' test or spherocytosis and no evidence of
diseases that could trigger IMHA. The clinical and laboratory data at
the time of diagnosis and the response to therapy and survival were
compared in dogs treated according to the prednisolone and azathioprine
protocol (AP protocol; n = 149) and dogs treated according to the
prednisolone protocol (P protocol; n = 73). At study entry, the two
groups were comparable, except that thrombocyte counts were
significantly lower and clinical signs had been present significantly
longer in the AP protocol group. No significant difference in survival
was found between the two groups: the 1-year survival was 64% (95% CI 54
- 77%) in the P protocol group and 69% (95% CI 59-80%) in the AP
protocol group, respectively.
Conclusions
Azathioprine would appear not to be beneficial as standard treatment
for all cases of IMHA; however, a blinded, randomized clinical trial is
needed to establish whether outcome is different with the two treatment
protocols.